Gold prices near 3-week lows as stronger dollar, trade progress weigh
C4 Therapeutics Inc. shares have tumbled to a 52-week low, with the stock price touching $1.95, marking a significant downturn for the biotech firm. The stock has plunged 72.5% over the past year, with particularly steep losses of 65% in the last six months. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 5.7x, though it’s currently burning through cash rapidly. This stark drop reflects investor concerns and broader market trends that have unfavorably impacted the biopharmaceutical sector, particularly companies focused on innovative but high-risk therapeutic research and development. C4 Therapeutics, known for its work in targeted protein degradation, faces a critical period ahead as it strives to regain investor confidence and stabilize its share price. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels, with 10 additional ProTips available to subscribers providing deeper insights into the company’s financial health and prospects.
In other recent news, C4 Therapeutics, Inc. has outlined its anticipated milestones for 2025, focusing on the advancement of its protein degradation therapies. The company plans to complete important phases in its clinical development programs for drug candidates such as cemsidomide and CFT1946. Cemsidomide has finished its Phase 1 dose escalation, with data expected in the second half of 2025. Additionally, the company is preparing for the next phase of clinical development for multiple myeloma, with studies set to begin in early 2026. CFT1946 is also progressing through its Phase 1 trial, with dose escalation expected to complete in the first half of 2025, and data anticipated later that year. The company’s partner, Betta Pharmaceuticals, is conducting a Phase 1 dose escalation study of CFT8919 in Greater China for non-small cell lung cancer patients. C4 Therapeutics expects its current financial resources to support operations into 2027. The company continues to leverage its TORPEDO® platform to develop orally bioavailable degraders for both oncology and non-oncology targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.